FDA Fast Tracks AiCuris' Cytomegalovirus Drug AIC246
By Cormac Sheridan
Friday, September 2, 2011
AiCuris GmbH & Co. KG gained FDA fast-track designation and valuable mindshare for its lead drug AIC246 (letermovir), a viral terminase inhibitor that combats human cytomegalovirus (CMV) infection. It is currently undergoing a Phase IIb trial in bone marrow transplant recipients, who are receiving the drug prophylactically, in order to prevent the dormant virus from re-emerging and causing active infection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.